Impact of adjuvant intrabladder therapy on quality of life in patients, suffering musculo-noninvasive cancer of the bladder
Objective. Comparative estimation of quality of life in patients with a high-risk musculo-noninvasive cancer of the bladder was accomplished while conduction of adjuvant intrabladder hyperthermic chemotherapy and immunotherapy with BCG vaccine.
Маterials and methods. Depending on kind of treatment, the patients were distributed into two groups: Group I - 44 patients, to whom adjuvant intrabladder immunotherapy with BCG vaccine was applied, and Group II - 41 patients, to whom intrabladder chemotherapy was conducted, using the system for local hyperthermy Combat BRS.
Results. The data from the patients interviewed, using EORTC QLQ-30 questionnaires, confirmed better quality of life in patients of Group II, who obtained intrabladder hyperthermic chemotherapy, peculiarly in accordance to indices of physical status, social adaptation and intoxication. In accordance to data of the patients’ interviewed with the help of FACT-BL questionnaire, also better results were obtained in patients of Group II in accordance to the social and functional well-being status, the urination quality and values of indices of the «Cancer of the Bladder» scale.
Conclusion. Higher quality of life was noted in patients of Group II, who obtained intrabladder hyperthermic chemotherapy. The lower quality of life in patients of Group I, who obtained immunotherapy with BCG vaccine, was connected with multiple side effects and enhanced toxicity of this therapy, accordingly.
Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019;76(5):639-57. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20. PMID: 31443960.
Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209-16. doi: 10.1046/j.1464-410x.2001.02306.x. PMID: 11488731.
Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216-23. doi: 10.1016/j.urology.2005.12.014. PMID: 16765182.
Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485-90. doi: 10.1111/j.1464-410x.2003.04655.x. PMID: 15008714.
Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247-56. doi: 10.1016/j.eururo.2009.04.038. Epub 2009 Apr 24. PMID: 19409692.
Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003 Jan;169(1):90-5. doi: 10.1097/01.ju.0000039680.90768.b3. PMID: 12478111.
Tan WP, Chang A, Brousell SC, Grimberg DC, Fantony JJ, Longo TA, et al. Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study. Int J Hyperthermia. 2020;37(1):854-60. doi: 10.1080/02656736.2020.1780328. PMID: 32664768.
Bello AP, Villacampa F, Goizueta JD, Rios E, Rimington P, Castillo J, et al. MP83-09 Chemohyperthermia with Mitomycin C and Combat System a New Alternative to BCB in High Risk non Muscle Invasive Bladder Cancer? Urol. 2018;199(4S):e1119. doi:10.1016/j.juro.2018.02.2757
Jong J, Hendricksen K, Rosier M, Boormans J, Mostafid H. PD66-11 Hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urol. 2018;199(4S): e1234-e1235. doi:10.1016/j.juro.2018.02.3007.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76. doi: 10.1093/jnci/85.5.365. PMID: 8433390.
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. EORTC QLQ-C30 Scoring Manual (3rd edition). Brussels: EORTC; 2001. ISBN: 2-9300 64-22-6.
Coast J, Peters TJ, Richards SH, Gunnell DJ. Use of the EuroQoL among elderly acute care patients. Qual Life Res. 1998;7(1):1-10. doi: 10.1023/a:1008857203434. PMID: 9481146.
Frei E 3rd. Randomized clinical trials and other approaches in clinical research. Cancer. 1994;74(9 Suppl):2610-3. doi: 10.1002/1097-0142(19941101)74:9+<2610::aid-cncr2820741804>3.0.co;2-c. PMID: 7954273.
Simons JP, Aaronson NK, Vansteenkiste JF, ten Velde GP, Muller MJ, Drenth BM, et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol. 1996;14(4):1077-84. doi: 10.1200/JCO.19184.108.40.2067. PMID: 8648360.
This work is licensed under a Creative Commons Attribution 4.0 International License.